#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1

• https://x.com/Yuz6Yusof/status/2063262556358099167/photo/1
• https://x.com/Yuz6Yusof/status/2063262556358099167/photo/1

🏠 Take Home Messages from the early #axSpA session 🔺 Earlier diagnosis is possible and better 🔺 Early axSpA is not synonymous to mild 🔺 Longitudinally, early axSpA is heterogeneous 🔺 MRI has transformed the field ❗️Beware of pitfalls #EULAR2026 @RheumNow

A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype Results from the Spanish REGISPON-3 POS1352 #EULAR2026 @RheumNow https://t.co/XicguAdXJ1

• https://x.com/Nellziade/status/2063265343502442821/photo/1

How many patients with IBD have axSpA? POS1338 #EULAR2026 @RheumNow ⬇️⬇️⬇️ https://t.co/29qkrCnDYz

• https://x.com/Nellziade/status/2063266451654340938/photo/1

Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU? Yes! POS 1347 Multicenter randomised open-label trial N=56 #EULAR2026 @RheumNow https://t.co/kP7ropPkpC

• https://x.com/Nellziade/status/2063267473172934848/photo/1

What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission? Data from 194 patients from the SELECT-AXIS2 RCT: ▶️ Remission maintained in 1/4 at48 weeks POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux

• https://x.com/Nellziade/status/2063269000612561273/photo/1

#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD

• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1

https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t

• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://twitter.com/eular_ard/status/2062509665024344391

LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK

• https://x.com/synovialjoints/status/2063217409222148317/photo/1

#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP

• https://x.com/Yuz6Yusof/status/2063217963818266828/photo/1

ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte

• https://x.com/synovialjoints/status/2063218464748179676/photo/1

First head-to-head trial to show #PsA joint outcome superiority BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%. @RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD

• https://x.com/JihaRheum/status/2063218845842571488/photo/1

Abstr LB0003 Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered. RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia

• https://x.com/synovialjoints/status/2063222707315974230/photo/1

#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN

• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1
• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1